Profile data is unavailable for this security.
About the company
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
- Revenue in USD (TTM)1.21bn
- Net income in USD-365.46m
- Incorporated2007
- Employees3.28k
- LocationNatera Inc13011 MCCALLEN PASSBUILDING A SUITE 100AUSTIN 78753United StatesUSA
- Phone+1 (650) 249-9090
- Fax+1 (302) 674-5266
- Websitehttps://www.natera.com/
More ▼
Mergers & acquisitions
| Acquired company | NTRA:NSQ since announced | Transaction value |
|---|---|---|
| Invitae Corp-Reproductive Health Assets | 59.78% | 52.50m |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corp | 2.53bn | -240.23m | 9.30bn | 6.50k | -- | 2.96 | -- | 3.67 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Repligen Corp | 607.45m | 14.84m | 9.61bn | 1.78k | 681.17 | 4.87 | 113.74 | 15.82 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Catalent Inc | 4.14bn | -1.18bn | 10.02bn | 17.80k | -- | 2.76 | -- | 2.42 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 11.42bn | 20.00k | 26.00 | 3.14 | 14.76 | 2.78 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| United Therapeutics Corporation | 2.50bn | 1.05bn | 12.16bn | 1.17k | 12.98 | 2.27 | 11.01 | 4.87 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Medpace Holdings Inc | 1.96bn | 312.32m | 12.19bn | 5.80k | 40.08 | 18.10 | 35.85 | 6.21 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.42bn | 1.31k | 1,649.05 | 12.92 | 211.44 | 8.85 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Incyte Corp | 3.77bn | 745.44m | 12.82bn | 2.52k | 17.34 | 2.38 | 15.43 | 3.40 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Natera Inc | 1.21bn | -365.46m | 13.01bn | 3.28k | -- | 16.39 | -- | 10.77 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Viatris Inc | 15.36bn | -56.10m | 13.07bn | 38.00k | -- | 0.6531 | 4.94 | 0.8511 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| BIO-TECHNE Corp | 1.15bn | 202.97m | 13.21bn | 3.05k | 66.64 | 6.55 | 42.12 | 11.44 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.32bn | 1.45k | 39.10 | 6.00 | 36.51 | 7.22 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.73bn | 3.40k | 73.42 | 2.90 | 47.39 | 5.96 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Data as of May 17 2024. Currency figures normalised to Natera Inc's reporting currency: US Dollar USD
39.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 10.87m | 9.00% |
| Fred Alger Management LLCas of 31 Dec 2023 | 6.29m | 5.21% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 5.69m | 4.71% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.53m | 4.58% |
| Samlyn Capital LLCas of 31 Dec 2023 | 3.87m | 3.21% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 3.47m | 2.88% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.19m | 2.64% |
| AllianceBernstein LPas of 31 Dec 2023 | 2.99m | 2.48% |
| Invesco Advisers, Inc.as of 31 Dec 2023 | 2.63m | 2.18% |
| RTW Investments LPas of 31 Dec 2023 | 2.59m | 2.15% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
